LENSAR, Inc. (NASDAQ:LNSR – Get Free Report) Director Elizabeth O’farrell sold 10,961 shares of LENSAR stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $4.97, for a total transaction of $54,476.17. Following the sale, the director owned 67,368 shares in the company, valued at $334,818.96. This represents a 13.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
LENSAR Trading Down 4.3%
NASDAQ LNSR opened at $4.64 on Friday. The company’s fifty day simple moving average is $6.16 and its 200-day simple moving average is $7.02. LENSAR, Inc. has a 52 week low of $4.30 and a 52 week high of $12.94. The stock has a market cap of $57.03 million, a P/E ratio of -11.60 and a beta of 1.03.
LENSAR (NASDAQ:LNSR – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.28). LENSAR had a net margin of 56.07% and a return on equity of 1,254.25%. The firm had revenue of $14.13 million during the quarter, compared to analysts’ expectations of $14.30 million.
Institutional Trading of LENSAR
Several institutional investors have recently added to or reduced their stakes in LNSR. Bank of New York Mellon Corp bought a new position in LENSAR during the 2nd quarter valued at $58,000. Engineers Gate Manager LP bought a new stake in shares of LENSAR in the 2nd quarter worth about $63,000. State of Wyoming acquired a new stake in shares of LENSAR in the 3rd quarter valued at about $110,000. Sanctuary Advisors LLC acquired a new stake in shares of LENSAR in the 2nd quarter valued at about $96,000. Finally, Royal Bank of Canada raised its stake in shares of LENSAR by 78.2% in the 1st quarter. Royal Bank of Canada now owns 20,095 shares of the company’s stock valued at $120,000 after purchasing an additional 8,818 shares in the last quarter. 40.15% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several analysts have recently weighed in on LNSR shares. Loop Capital set a $11.00 target price on LENSAR in a research note on Monday, September 28th. Lake Street Capital reiterated a “buy” rating and issued a $13.00 price target on shares of LENSAR in a research note on Thursday, August 13th. Weiss Ratings downgraded LENSAR from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday. Wall Street Zen lowered LENSAR from a “hold” rating to a “sell” rating in a research note on Saturday, November 14th. Finally, BTIG Research lowered their price objective on LENSAR from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, November 10th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $11.00.
Read Our Latest Research Report on LNSR
LENSAR Company Profile
LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens. The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.
Featured Articles
- Five stocks we like better than LENSAR
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
